Drugs / 3-[18F]Fluoro-para-hydroxyphenethylguanidine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04510311 | Oct 2020 → Dec 2024 | neuroendocrine neoplasm | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3-[18F]Fluoro-para-hydroxyphenethylguanidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04510311 ↗ |
| Route | Intravenous | “Single IV injection of 12.0 mCi (+/- 10%) \[18F\]3F-PHPG” NCT04510311 ↗ |